RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response

Clinical Cancer Research

Volumn 19, Issue 20, 2013, Pages 5686-5698

  Yin, Xuefeng ^a   Luistro, Leopoldo ^a   Zhong, Hua ^a   Smith, Melissa ^a   Nevins, Tom ^a   Schostack, Kathleen ^a   Hilton, Holly ^a   Lin, Tai An ^a   Truitt, Theresa ^a   Biondi, Denise ^a   Wang, Xiaoqian ^a   Packman, Kathryn ^a   Rosinski, Jim ^a   Berkofsky Fessler, Windy ^a   Tang, Jian Ping ^a   Pant, Saumya ^a   Geho, David ^a   Vega Harring, Suzana ^b   De Mario, Mark ^a   Levitsky, Hy ^c   Simcox, Mary ^a   more..

^a HOFFMANN LA ROCHE INC   (United States)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c Roche Glycart AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ERLOTINIB; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; PACLITAXEL; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN FN14; PROTEIN TWEAK; RECEPTOR PROTEIN; RG 7212; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; ENDOMETRIUM CARCINOMA; GENE EXPRESSION; GENETIC CORRELATION; HUMAN; HUMAN CELL; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MELANOMA; MONOCYTE; MONOTHERAPY; MOUSE; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR CELL LINE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR BURDEN; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84886412861     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0405     Document Type: Article

References (45)

1. Chicheportiche Y, Chicheportiche R, Sizing I, Thompson J, Benjamin CB, Ambrose C, et al. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 2002;4:126-33.
2. Kawakita T, Shiraki K,Yamanaka Y, Yamaguchi Y, Saitou Y, Enokimura N, et al. Functional expression of TWEAK in human colonic adenocarcinoma cells. Int J Oncol 2005;26:87-93.
3. Desplat-Jego S, Varriale S, Creidy R, Terra R, Bernard D, Khrestchatisky M, et al. TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J Neuroimmunol 2002;133: 116-23.
4. Michaelson JS, Cho S, Browning B, Zheng TS, Lincecum JM, Wang MZ, et al. Tweak induces mammary epithelial branching morphogenesis. Oncogene 2005;24:2613-24.
5. Kamata K, Kamijo S, Nakajima A, Koyanagi A, Kurosawa H, Yagita H, et al. Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis. J Immunol 2006;177: 6433-9.
6. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, Berens ME. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 2005;280:3483-92.
7. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001;15:837-46.
8. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997;272:32401-10.
9. Abbas AR, Baldwin D, Ma Y, Ouyang W, Gurney A, Martin F, et al. Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun 2005;6:319-31.
10. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/ Fn14 pathway in health and disease. Cytokine 2007;40:1-16.
11. Burkly LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev 2011;244:99-114.
12. Culp PA, Choi D, Zhang Y, Yin J, Seto P, Ybarra SE, et al. Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res 2010;16:497-508.
13. Pelekanou V, Notas G, Theodoropoulou K, Kampa M, Takos D, Alexaki VI, et al. Detection of the TNFSF members BAFF, APRIL, TWEAK and their receptors in normal kidney and renal cell carcinomas. Anal Cell Pathol (Amst) 2011;34:49-60.
14. Willis AL, Tran NL, Chatigny JM, Charlton N, Vu H, Brown SA, et al. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res 2008;6:725-34.
15. Kwon OH, Park SJ, Kang TW, Kim M, Kim JH, Noh SM, et al. Elevated fibroblast growth factor-inducible 14 expression promotes gastric cancer growth via nuclear factor-kappaB and is associated with poor patient outcome. Cancer Lett 2012;314:73-81.
16. Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, Symons M, et al. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factorkappaB and correlate with poor patient outcome. Cancer Res 2006; 66:9535-42.
17. Pettersen I, Baryawno N, Abel F, Bakkelund WH, Zykova SN, Winberg JO, et al. Expression ofTWEAK/Fn14 in neuroblastoma: implications in tumorigenesis. Int J Oncol 2013;42:1239-48.
18. Whitsett TG, Cheng E, Inge L, Asrani K, Jameson NM, Hostetter G, et al. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol 2012;181:111-20.
19. Varfolomeev E, Goncharov T, Maecker H, Zobel K, Komuves LG, Deshayes K, et al. Cellular inhibitors of apoptosis are global regulators of NF-kappaB and MAPK activation by members of the TNF family of receptors. Sci Signal 2012;5:ra22.
20. Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol 2012;4: pii: a006049.
21. Dohi T, Burkly LC. The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases; focus on inflammatory bowel diseases. J Leukoc Biol 2012;92:265-79.
22. Liu ZC, Zhou QL. Tumor necrosis factor-like weak inducer of apoptosis and its potential roles in lupus nephritis. Inflamm Res 2012;61:277-84.
23. Izquierdo MC, Sanz AB, Mezzano S, Blanco J, Carrasco S, Sanchez-Nino MD, et al. TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. Kidney Int 2012;81:1098-107.
24. Iocca HA, Plant SR, Wang Y, Runkel L, O'Connor BP, Lundsmith ET, et al. TNF superfamily member TWEAK exacerbates inflammation and demyelination in the cuprizone-induced model. J Neuroimmunol 2008;194:97-106.
25. Zhao Z, Burkly LC, Campbell S, Schwartz N, Molano A, Choudhury A, et al.TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 2007;179:7949-58.
26. Broll K, Richter G, Pauly S, Hofstaedter F, Schwarz H. CD137 expression in tumor vessel walls. High correlation with malignant tumors. Am J Clin Pathol 2001;115:543-9.
27. Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006;27:242-50.
28. Park MC, Chung SJ, Park YB, Lee SK. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. Scand J Rheumatol 2008;37:173-8.
29. Ikner A, Ashkenazi A. TWEAK induces apoptosis through a deathsignaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8. J Biol Chem 2011;286:21546-54.
30. Michaelson JS, Amatucci A, Kelly R, Su L, Garber E, Day ES, et al. Development of an Fn14 agonistic antibody as an anti-tumor agent. mAbs 2011;3:362-75.
31. Fortin SP, Ennis MJ, Savitch BA, Carpentieri D, McDonough WS, Winkles JA, et al. Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function. Mol Cancer Res 2009;7:1871-81.
32. Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, et al. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003;23:594-600.
33. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999;274:8455-9.
34. Ho DH, Vu H, Brown SA, Donohue PJ, Hanscom HN, Winkles JA. Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res 2004;64:8968-72.
35. Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, Lee W, et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell 2005;123:931-44.
36. Lassen U, Meulendijks D, Siu LL, Jonker D, Sorensen M, Schellens JHM, et al. A first-in-human phase I monotherapy study of RG7212, a novel monoclonal antibody targeting TWEAK signaling in patients with advanced solid tumors. Eur J Cancer 2012;48:12.
37. Dineen SP, Sullivan LA, Beck AW, Miller AF, Carbon JG, Mamluk R, et al. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 2008;8:352.
38. Porembka MR, Mitchem JB, Belt BA, Hsieh CS, Lee HM, Herndon J, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother 2012;61:1373-85.
39. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131-44.
40. Hayden MS, Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012;26:203-34.
41. Sun SC. Non-canonical NF-kappaB signaling pathway. Cell Res 2011;21:71-85.
42. Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 2012;167: 195-205.
43. Bellail AC, Olson JJ, Yang X, Chen ZJ, Hao C. A20 ubiquitin ligasemediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov 2012; 2:140-55.
44. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
45. Oldham KA, Parsonage G, Bhatt RI, Wallace DM, Deshmukh N, Chaudhri S, et al. T lymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6. Eur Urol 2012;61:385-94.